Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:1-DeoxyCer 18:0;O/24:1)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004093 AN006783 Autoimmune Disease Risk Gene ANKRD55 Promotes T Cell Proliferation and Th17 2 Effector Function Through Metabolic Modulation T-cells Mouse Autoimmune disease Broad Institute of MIT and Harvard LC-MS
ST003805 AN006254 Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders Brain Mouse Neurodevelopment Disorder Broad Institute of MIT and Harvard LC-MS
ST003805 AN006254 Epigenetic changes, neuronal dysregulation and behavioral abnormalities in Zmym2+/- mutant mice, a genetic animal model of schizophrenia and neurodevelopmental disorders Brain Mouse Schizophrenia Broad Institute of MIT and Harvard LC-MS
ST002344 AN003828 The impact of dietary serine/glycine restriction and myriocin treatment on hepatic sphingolipid diversity during prolonged high fat diet feeding. Liver Mouse Salk Institute for Biological Studies LC-MS
ST002343 AN003827 The impact of myriocin and dietary serine restriction on paw skin sphingolipid diversity Skin Mouse Salk Institute for Biological Studies LC-MS
ST002340 AN003823 Serine supplementation and hepatic and skin sphingolipid diversity Liver Mouse Salk Institute for Biological Studies LC-MS
ST002340 AN003823 Serine supplementation and hepatic and skin sphingolipid diversity Skin Mouse Salk Institute for Biological Studies LC-MS
ST002284 AN003732 Genetically defined human GBM organoids reveal principles of GBM development and actionable targets Cultured cells Human Cancer DKFZ LC-MS
ST000917 AN001501 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine Urine Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000916 AN001495 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma Blood Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000915 AN001489 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver Liver Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
  logo